Risk Estimation Errors in Glaucoma Treatment: Balancing Surgery and Medication

Overview

Glaucoma treatment decisions are often influenced by errors in risk estimation, leading to either overcautious avoidance of surgery or overly aggressive surgical intervention. Understanding and correcting these biases can improve patient outcomes by appropriately balancing the risks of treatment complications against the risk of progressive vision loss.

Background

Glaucoma is a progressive, irreversible disease that can lead to blindness if not managed effectively. Treatment options include medications, minimally invasive glaucoma surgeries (MIGS), and more invasive surgical procedures. Physicians often face challenges in weighing the risks of treatment-related complications against the risk of disease progression. Misestimation of these risks can result in errors of omission, where necessary interventions are withheld, or errors of commission, where unnecessary or premature interventions are performed.

Data Highlights

A large study involving approximately 40,000 patients found no increased risk of acute cystoid macular edema (CME) with prostaglandin analogs (PGAs); in fact, PGA users had a lower risk of CME compared to users of other topical glaucoma medications. The Advanced Glaucoma Intervention Study (AGIS) demonstrated that maintaining intraocular pressure below 14 mm Hg is associated with stability in glaucoma progression.

Key Findings

• Glaucoma surgery prevents more blindness than it causes, despite concerns about surgical complications.
• Physicians tend to overestimate small risks (e.g., transient hyphema after MIGS) and underestimate large risks (e.g., vision loss from untreated glaucoma).
• Fear of prostaglandin analog–induced CME is unfounded based on large-scale data, yet it leads to underutilization of effective medications.
• Errors of omission occur when surgeons avoid surgery due to fear of complications, potentially allowing disease progression.
• Errors of commission occur when surgeons operate aggressively on all patients above a strict intraocular pressure target, possibly exposing patients to unnecessary surgical risks.
• New drug delivery methods and interventional therapies are underused partly due to misperceptions about their risks.

Clinical Implications

Clinicians should carefully balance the risks of glaucoma progression against the risks of treatment complications, avoiding both excessive caution and unnecessary intervention. Educating providers about the true risk profiles of medications and surgical procedures can enhance treatment adherence and optimize patient outcomes. Early and appropriately aggressive intervention remains critical in preventing irreversible vision loss.

Conclusion

Accurate risk estimation is essential in glaucoma management to prevent vision loss while minimizing treatment-related harm. Recognizing and correcting biases can lead to better utilization of available therapies and improved patient care.

References

1. The AGIS Investigators 2000 -- The relationship between control of intraocular pressure and visual field deterioration
2. Zhou Y et al. 2025 -- Incidence of acute cystoid macular edema after starting a prostaglandin analog compared with other classes of glaucoma medications